See more : FS KKR Capital Corp. (FSK) Income Statement Analysis – Financial Results
Complete financial analysis of Lyell Immunopharma, Inc. (LYEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lyell Immunopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Trane Technologies plc (TT) Income Statement Analysis – Financial Results
- LGMS Berhad (0249.KL) Income Statement Analysis – Financial Results
- Bowleven plc (BWLVF) Income Statement Analysis – Financial Results
- Triterras, Inc. (TRIRF) Income Statement Analysis – Financial Results
- Thailand Future Fund (TFFIF.BK) Income Statement Analysis – Financial Results
Lyell Immunopharma, Inc. (LYEL)
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 130.00K | 84.68M | 10.65M | 7.76M | 657.00K |
| Cost of Revenue | 0.00 | 16.47M | 14.54M | 7.48M | 0.00 |
| Gross Profit | 130.00K | 68.22M | -3.89M | 281.00K | 657.00K |
| Gross Profit Ratio | 100.00% | 80.55% | -36.48% | 3.62% | 100.00% |
| Research & Development | 182.95M | 159.19M | 138.69M | 182.24M | 63.60M |
| General & Administrative | 66.98M | 117.31M | 89.06M | 46.88M | 39.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.98M | 117.31M | 89.06M | 46.88M | 39.15M |
| Other Expenses | -2.79M | 1.89M | -2.32M | -9.43M | -35.41M |
| Operating Expenses | 247.14M | 276.50M | 225.43M | 219.69M | 102.75M |
| Cost & Expenses | 247.14M | 276.50M | 225.43M | 219.69M | 102.75M |
| Interest Income | 23.45M | 7.05M | 1.17M | 5.94M | 8.12M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 20.25M | 16.47M | 14.54M | 7.48M | 4.38M |
| EBITDA | -226.76M | -166.65M | -199.94M | -207.64M | -100.83M |
| EBITDA Ratio | -174,429.23% | -194.96% | -1,546.53% | -2,677.19% | -15,347.49% |
| Operating Income | -247.01M | -183.12M | -214.78M | -211.94M | -102.09M |
| Operating Income Ratio | -190,006.15% | -216.24% | -2,016.68% | -2,732.56% | -15,538.66% |
| Total Other Income/Expenses | 12.38M | 3.84M | -36.65M | 7.47M | -27.29M |
| Income Before Tax | -234.63M | -183.12M | -250.22M | -204.47M | -129.38M |
| Income Before Tax Ratio | -180,486.15% | -216.24% | -2,349.47% | -2,636.31% | -19,692.09% |
| Income Tax Expense | 0.00 | -178.36M | 35.28M | -5.94M | -8.12M |
| Net Income | -234.63M | -4.75M | -285.50M | -198.53M | -121.26M |
| Net Income Ratio | -180,486.15% | -5.61% | -2,680.76% | -2,559.73% | -18,456.01% |
| EPS | -0.93 | -0.02 | -1.18 | -0.81 | -0.49 |
| EPS Diluted | -0.93 | -0.02 | -1.18 | -0.81 | -0.49 |
| Weighted Avg Shares Out | 250.98M | 247.08M | 242.74M | 246.58M | 246.58M |
| Weighted Avg Shares Out (Dil) | 250.98M | 247.08M | 242.74M | 246.58M | 246.58M |
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that members of its senior management...
Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL
Lyell Immunopharma results from a phase 1 study using LYL797 for the treatment of relapsed/refractory NSCLC and TNBC patients with ROR1 expression expected in the 1st half of 2024. Results from phase 1 study using LYL845 for the treatment of...
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that the U.S. Food and Drug...
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T‑cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for...
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials in progress Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and...
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform
SOUTH SAN FRANCISCO. Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Lyell Immunopharma (NASDAQ: LYEL), a clinical‑stage T-cell reprogramming company advancing a...
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform
Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell Shuttle Collaboration to evaluate potential utilization of the Cell Shuttle for future Lyell CAR T-cell clinical trials and commercialization SOUTH SAN FRANCISCO, Calif. ,...
Lyell Immunopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management...
Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data
Lyell is a developer of personalized T-cell therapies for solid tumors, with two programs targeting various types of solid tumors. Their pipeline includes LYL797, a CART cell targeting TNBC and NSCLC, and LYL845, a TIL targeting melanoma, NSCLC, and CRC....
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for...
Source: https://incomestatements.info
Category: Stock Reports